REG - Hikma Pharmaceutical - Hikma appoints new President of Injectables

Hikma PharmaceuticalsAnnouncement

09/08/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230809:nRSI7127Ia&default-theme=true

RNS Number : 7127I  Hikma Pharmaceuticals Plc  09 August 2023

Hikma appoints new President of Injectables business

London, 9 August 2023 - Hikma Pharmaceuticals PLC and its subsidiaries
('Hikma' or 'Group'), the multinational pharmaceutical company, announce that
Dr. Bill Larkins has been appointed President of its Injectables business,
effective 1 September 2023. Bill will be based in the US and report to Riad
Mishlawi in his new role as Hikma's Chief Executive Officer.

Bill has extensive experience in the sterile injectable generic market. He was
previously Chief Executive Officer of Custopharm, which was acquired by Hikma
in 2022 and has since been Hikma´s Senior Vice President, R&D,
Injectables.

During his career, Bill has held senior leadership roles at leading injectable
pharmaceutical companies including Bedford Laboratories and ESI
Lederle/Baxter. He also played a significant role at Schein Pharmaceuticals'
Steris Laboratories in Phoenix and at Amylin Pharmaceuticals, where he worked
on the development of complex injectable medicines.

Commenting on the appointment, Riad Mishlawi, President of Injectables /
CEO-elect said: "Bill's exceptional leadership skills, vast expertise, and
successful track record make him the ideal person to lead our Injectables
team. Over the next few years, we have a tremendous opportunity to further
expand Hikma's position as a market-leading manufacturer and supplier of
generic injectable medicines. I look forward to working with Bill in his new
role."

Dr. Bill Larkins added: "This is a very exciting opportunity for me to lead a
highly talented team, who have been growing and developing this business so
successfully over the years. I am confident that we can continue to leverage
our differentiated R&D pipeline, capacity expansion projects and new
businesses to further enhance our position as one of the leading providers of
injectable medicines across our geographies."

- ENDS -

Hikma (Investors):

 Susan Ringdal                                +44 (0)20 7399 2760/ +44 (0)7776 477050

 EVP, Strategic Planning and Global Affairs
 Guy Featherstone                             +44 (0)20 3892 4389/ +44 (0)7795 896738

 Associate Director, Investor Relations
 Layan Kalisse                                +44 (0)20 7399 2788/ +44 (0)7970 709912

 Senior Associate, Investor Relations

 

Teneo (Press):
 

Charles Armitstead / Rob
Yates                           +44 (0)7703 330269/
+44 (0)7715 375443

About Hikma:

Hikma helps put better health within reach every day for millions of people
around the world. For more than 45 years, we've been creating high-quality
medicines and making them accessible to the people who need them.
Headquartered in the UK, we are a global company with a local presence across
North America, the Middle East and North Africa (MENA) and Europe, and we use
our unique insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed to our
customers, and the people they care for, and by thinking creatively and acting
practically, we provide them with a broad range of branded and non-branded
generic medicines. Together, our 8,700 colleagues are helping to shape a
healthier world that enriches all our communities. We are a leading licensing
partner, and through our venture capital arm, are helping bring innovative
health technologies to people around the world. For more information, please
visit: www.hikma.com
(https://nam04.safelinks.protection.outlook.com/?url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2531421-1%26h%3D3823969217%26u%3Dhttp%253A%252F%252Fwww.hikma.com%252F%26a%3Dwww.hikma.com&data=02%7C01%7Csweiss%40Hikma.com%7C4a35048c8c764c63c86308d70efbac9e%7C178c1a723d3c40afbaa754615303bcdc%7C0%7C1%7C636994346427346162&sdata=lHZaoOb0u30Y6re6yfLW1Ar4vvBS%2FnjEUNdB00TBaTI%3D&reserved=0)

 

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY)
(LEI:549300BNS685UXH4JI75) (rated BBB-/stable S&P and BBB-/positive Fitch)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAVVLFBXVLBBBX